In a recent development, the Justice Department has decided not to pursue Foreign Corrupt Practices Act (FCPA) prosecution against Lifecore Biomedical, as per its Corporate Enforcement Policy. This decision marks one of the latest actions under the policy in 2023, and helps underline important strategic decisions within the Justice Department’s operational framework.
For reference, in 2023, three corporate FCPA enforcement actions have been brought forward by the Justice Department, including the significant Ericsson DPA breach settlement. However, with the recent Lifecore Biomedical decision, the Department of Justice (DOJ) has declined a total of two FCPA cases, alongside one healthcare fraud case in the same year (The Volkov Law Group) .
The Corporate Enforcement Policy, an instrumental part of the Justice Department’s FCPA prosecutions, incentivizes Corporations to voluntarily disclose any potential FCPA misconduct. The intention is to foster corporate compliance with transparency in business operations. However, specific details about the Lifecore Biomedical case have not been disclosed in light of this recent declination.
It’s important for legal professionals at global corporations and law firms to stay updated on these developments, as they underscore emergent trends in FCPA enforcement, corporate compliance expectations, and risk management strategies. Understanding these cases can help organizations prepare for their interactions with the Justice Department, and better manage compliance risks within their operations.